Clinical Trials
FDA approves linagliptin tablets for the treatment of type 2 diabetes
Boehringer Ingelheim and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along...
Clinical Trials
Gilead and MicroDose Therapeutx Announce License and Collaboration Agreement to Develop MDT-637
Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the...
Clinical Trials
Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on AVONEX PEN
Biogen Idec announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval...
Clinical Trials
Boehringer Ingelheim’s lead hepatitis C compound moves into phase III – the first within the BI HCV portfolio
Boehringer Ingelheim announced the study outline for the pivotal Phase III clinical trials designed to evaluate BI 201335, its investigational once-daily oral protease inhibitor, in...
Clinical Trials
Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID)
Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today the initiation of a Phase IIa clinical trial to evaluate dipraglurant in patients with Parkinson’s disease...
Clinical Trials
Adocia reports positive phase I clinical results on HinsBet(R), a fast-acting human insulin
Adocia, a privately-held biotechnology company specialized in regenerative medicine and in the treatment of chronic diseases, announced today positive results from its phase I clinical...
Clinical Trials
Infinity Initiates Phase 2 Trial of IPI-926 in Patients With Chondrosarcoma
Infinity Pharmaceuticals, Inc. announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.